Tuesday, October 13, 2026

USD/EUR Over 1% Up In The Last 21 Sessions

ViaNews Editorial Team

February 17, 2023

USD/EUR Over 1% Up In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.76% for the last 21 sessions. At 09:06 EST on Friday, 17 February, USD/EUR (USDEUR) is $0.94.

USD/EUR's yearly highs and lows, it's 6.934% up from its 52-week low and 10.399% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.12%, 0.16%, and 0.45%, respectively.

USD/EUR's highest amplitude of average volatility was 0.25% (last week), 0.44% (last month), and 0.45% (last quarter), respectively.

News about

  • Usd/jpy price analysis: bulls flirt with 133.00 inside monthly rising wedge. According to FXStreet on Wednesday, 15 February, "Even if the quote rises past 133.60, a two-month-old horizontal resistance region near 134.50-70, will precede the 200-DMA level surrounding 136.90 to challenge the USD/JPY bulls.", "It should be noted that the 130.00 round figure will act as an extra filter towards the south of 130.60 before directing the USD/JPY sellers towards the theoretical target of the stated wedge, namely 125.50."
  • Usd/jpy holds steady near its highest level since January, just below mid-133.00s. According to FXStreet on Wednesday, 15 February, "The USD/JPY pair attracts some dip-buying near the mid-132.00s and turns positive for the third successive day on Wednesday. ", "This is seen as another factor lending support to the JPY and keeping a lid on the USD/JPY pair."
  • Usd/jpy retreats towards 133.50 as Japan trade data, boj concerns battle with fed bets. According to FXStreet on Thursday, 16 February, "A convergence of the one-month-old previous resistance line and the 200-day Exponential Moving Average (EMA), highlights 133.75 as the short-term key support for the USD/JPY traders to watch."
  • Usd/jpy snaps two-day uptrend despite upbeat yields, hawkish fed talks. According to FXStreet on Wednesday, 15 February, "That said, S&P 500 Futures trace Wall Street's downbeat closing to highlight the mildly offbeat mood and weigh on the USD/JPY prices, mainly due to the Japanese Yen's (JPY) traditional risk-safety allure.", "Unless providing a daily close beyond the 200-day Exponential Moving Average (EMA), the USD/JPY pair remains on the bear's radar."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com